K

S

SV Health Investors

Crunchbase
Pitchbook
Crunchbase

Deals on record

12

Common Fundraising Type

Equity

M
Montara Therapeutics

Biotech • Brain-selective therapies

Two Bear Capital logo
SV Health Investors logo
KdT Ventures logo
Dolby Family Ventures logo

Montara Therapeutics is a biotech company developing brain-selective therapies for central nervous system diseases using their BrainOnly™ platform.

Seed
$20M
03/13/2025
Article
P
Perfuze

Medical devices • Catheters

SV Health logo
Seroba logo
EQT Life Sciences logo
Earlybird logo

Perfuze is a medical device company that develops catheters designed to improve stroke treatment by enhancing the trackability and delivery of aspiration catheters.

Equity
$23.9M
03/13/2025
Article
T
TRIMTECH Therapeutics

Biotech • Targeted protein degradation

SV Health Investors logo
Cambridge Innovation Capital logo
Pfizer Ventures logo
MP Healthcare Venture Management logo

TRIMTECH Therapeutics is a biotech company developing targeted protein degradation therapeutics for neurodegenerative diseases using TRIMTAC degrader molecules.

Seed
$32M
03/05/2025
Article
A
AdvanCell

Radiopharmaceutical • Clinical-stage

SV Health Investors logo
SymBiosis logo
Sanofi Ventures logo
Morningside logo

AdvanCell is a clinical-stage radiopharmaceutical company developing innovative cancer therapies using targeted alpha-emitting radionuclides.

Series C
$112M
02/03/2025
Article
T
TRexBio

Biotechnology • Inflammatory Diseases

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
L
LoQus23 Therapeutics

Biotech • Small molecule drugs

Forbion logo
SV Health Investors logo
Novartis logo

LoQus23 Therapeutics develops small molecule drugs to halt DNA instability and slow neurodegeneration in triplet repeat diseases like Huntington's disease.

Series A
$46.5M
10/02/2024
Article
S
SpectraWAVE

Medical imaging • Coronary stenting

SV Health Investors logo
S3 Ventures logo
NovaVenture logo
Johnson & Johnson Innovation - JJDC logo

SpectraWAVE, Inc. develops advanced medical imaging systems to improve coronary stenting procedures and enhance clinical decision-making in the treatment of coronary artery disease.

Series B
$50M
09/11/2024
Article
C
CSA Medical

Medical device • Chronic bronchitis

TVM Capital Life Science logo
Yonjin Ventures logo
SV Health Investors logo
Intersouth Partners logo

CSA Medical Inc. develops and commercializes the RejuvenAir System, a medical device designed to treat chronic bronchitis.

Series D
$53M
09/09/2024
Article
H
Harness Therapeutics

Biotech • Neurodegenerative Diseases

Takeda Ventures logo
SV Health Investors logo

Harness Therapeutics is a biotech firm specializing in creating oligonucleotide-based drugs to treat neurodegenerative diseases by upregulating protein expression, with a current focus on advancing a treatment for Huntington's Disease towards clinical trials.

Equity
$5.1M
11/30/2023
Article
E
EyeBio

Ophthalmology Biotechnology • Clinical-Stage

Vertex Ventures HC logo
Omega Funds logo
SV Health Investors logo
Samsara Biocapital logo

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.

Series A
$65M
11/14/2023
Article
S
Sitryx Therapeutics

Biopharmaceutical • Immunometabolism

GSK logo
SV Health Investors logo
Sofinnova Partners logo
Oxford Science Enterprises logo

Sitryx Therapeutics is a biopharmaceutical company that develops disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by targeting and regulating cell metabolism.

Equity
$39M
09/27/2023
Article
N
Nimbus Therapeutics

Computational Drug Discovery • Immunology

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article